Toripalimab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Toripalimab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Toripalimab Today - Breaking & Trending Today

#VisualAbstract: Perioperative Toripalimab Plus Chemotherapy Improves Event-Free Survival in Patients With Resectable Non–Small-Cell Lung Cancer

Click here to read this study in JAMA Network Open. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, ....

Minute Medicine Inc , Lung Cancer , Lung Cancer Treatment , Non Small Cell Lung Cancer ,

Toripalimab Approval Pioneers Immunotherapy Use in Nasopharyngeal Cancer

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration. ....

Emory University , United States , Nabilf Saba , Junshi Biosciences , Coherus Biosciences , Howard Halpern , Shravan Kandula , Neck Cancer Multidisciplinary Program , Department Of Hematology , Neck Cancer Research , Medical Oncology , Emory University School , Howard Halpern Chair , Winship Cancer Institute , Adventhealth Medical Group Radiation Oncology , Central Florida , Shanghai Junshi , Chenq Y , Chend P , Pd 1 Inhibitor , Nasopharyngeal Carcinoma , Phase 3 Jupiter 02 Trial Nct03581786 , Phase 2 Polaris 02 Trial Nct02915432 ,

Coherus and Junshi Biosciences Announce FDA Approval of

– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy. ....

United States , Junshi Bioscience , Hill Knowlton , Coherus Biosciences , Jodi Sievers , Zhi Li , Ruihua Xu , Judy Stecker , Junshi Biosciences , Denny Lanfear , Exchange Commission , Drug Administration , Hospital Cancer Center , Vp Corporate Communications , Administration In Prescribing Information , Shanghai Junshi Biosciences Co Ltd , Ir Team , Exchange Commission On , Pr Team , Harvard Medical School , Surface Oncology Inc , Neck Cancer Alliance , Coherus Biosciences Inc , Neck Cancer Foundation , Sun Yat Sen University Cancer Center , Public Affairs ,

FDA Approves Toripalimab for Recurrent or Metastatic Nasopharyngeal Carcinoma

The FDA has approved toripalimab-tpzi (Loqtorzi) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adult patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy. ....

Coherus Biosciences , Junshi Biosciences , Denny Lanfear , Shanghai Junshi , Fda Approval ,

China's NMPA Accepts sNDA for First-Line Toripalimab Plus Chemo in ES-SCLC

China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer. ....

Ying Cheng , Junshi Biosciences , Jianjun Zou , China National Medical Products Administration , Veterans Administration Lung Study Group , Global Research , Chinese Society Of Clinical Oncology , National Medical Products Administration , Thoracic Medical Oncology , Jilin Cancer Hospital , Chinese Society , Clinical Oncology , China X27s National Medical Products Administration , Extensive Stage Small Cell Lung Cancer ,